Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver ...

Exelixis’ next franchise in a drug, zanzalintinib, has hit a clinical setback, although at least two groups of analysts ...

EExelixis Inc. NASDAQ: EXEL) on Monday reported final overall survival data from the Phase 3 STELLAR-303 trial. The data ...

Exelixis' main franchise has helped it perform well in recent years. The biotech company is developing new, promising cancer drugs. While not the most popular biotech company on the market, Exelixis ...

Exelixis is back in focus as a refreshed fair value price target shifts from US$47.53 to US$49.65, reflecting updated assumptions in the latest analyst models. That new figure sits between recently ...

Exelixis remains undervalued despite a 13%+ rally post-Q1, supported by robust double-digit growth, sector-leading profitability, and strong free cash flow. Q1 revenue grew 10% year-over-year, driven ...

Exelixis (NASDAQ:EXEL) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...

Exelixis offers exceptional medium-term growth, driven by Cabometyx's market leadership and a robust pipeline, yet remains undervalued versus peers. EXEL maintains high profitability and growth ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent’s proprietary immuno-oncology (IO) ...